I-131

INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR FISCAL YEAR 2023

Retrieved on: 
Monday, April 1, 2024
Medical device, Thyroid cancer, Growth, The Twelve Months, Third party, Calibration, Sale, IDAHO, Intellectual property, I-131, OTCQB, Nuclear medicine, Cryptocurrency

IDAHO FALLS, Idaho, April 1, 2024 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company" or "INIS") announces its financial results for the twelve-month periods ended December 31, 2023.

Key Points: 
  • IDAHO FALLS, Idaho, April 1, 2024 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company" or "INIS") announces its financial results for the twelve-month periods ended December 31, 2023.
  • Revenue for the twelve months ended December 31, 2023, was $12.3 million compared to $11.2 million for the same period in 2022.
  • As of December 31, 2023, cash and cash equivalents improved to $2.7 million compared to $2.4 million as of December 31, 2022.
  • Shahe Bagerdjian, President & CEO of the Company, said, "The 2023 fiscal results are very encouraging; we posted the highest revenue in the company's history, and the company had positive cash flow from operating activities.

INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE THIRD QUARTER AND FIRST NINE MONTHS OF 2023

Retrieved on: 
Tuesday, November 14, 2023
Sale, Research, Thyroid cancer, OTCQB, IDAHO, Nuclear medicine, I-131, Third party, Growth, Nine Months, Clothing, Cryptocurrency

Revenues Increased 14% in the Nine Months Ended September 30, 2023;

Key Points: 
  • Revenues Increased 14% in the Nine Months Ended September 30, 2023;
    Operating Loss Improved 43% in the Nine Months Ended September 30, 2023; and
    Gross Profit Increased 19% Nine Months Ended September 30, 2023.
  • IDAHO FALLS, Idaho, Nov. 14, 2023 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company" or "INIS") announces its financial results for the three- and nine-month periods ended September 30, 2023.
  • Revenue for the nine months ended September 30, 2023, was $9,120,256 compared to $8,031,522 for the same period in 2022.
  • Revenue for the three months ended September 30, 2023, was $2,918,556 compared to $2,789,273 for the same period in 2022, an overall increase of approximately 5%.

INTERNATIONAL ISOTOPES INC. ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER 2023

Retrieved on: 
Tuesday, May 16, 2023
INIS, Sale, Nuclear medicine, Growth, OTCQB, PET, Acquisition, Cobalt, Positron emission tomography, IDAHO, I-131, Pharmaceutical industry

IDAHO FALLS, Idaho, May 16, 2023 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company") is pleased to announce its financial results for the three months ended March 31, 2023.

Key Points: 
  • IDAHO FALLS, Idaho, May 16, 2023 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company") is pleased to announce its financial results for the three months ended March 31, 2023.
  • Revenue for the three months ended March 31, 2023 was $3,089,535 as compared to $2,807,441 for the same period in 2022, an overall increase of approximately 10%.
  • This increase in revenue was the result of increased revenue in radiochemical and nuclear medicine standards segments.
  • The Company reported a 61% decrease in operating loss for the three-months ended March 31, 2023 compared to the same period in 2022.

INTERNATIONAL ISOTOPES INC. ANNOUNCES 2022 YEAR END FINANCIAL RESULTS

Retrieved on: 
Thursday, April 6, 2023
Maintenance, IDAHO, OTCQB, PET, Research, Nuclear medicine, DOE, Primary energy, Sale, INIS, Growth, FDA, Cobalt, Positron emission tomography, I-131, Cryptocurrency, Video game, Marketing

IDAHO FALLS, Idaho, April 6, 2023 /PRNewswire/ --  International Isotopes Inc. (OTCQB: INIS) (the "Company") announces its financial results for the fiscal year ended December 31, 2022. 

Key Points: 
  • IDAHO FALLS, Idaho, April 6, 2023 /PRNewswire/ --  International Isotopes Inc. (OTCQB: INIS) (the "Company") announces its financial results for the fiscal year ended December 31, 2022.
  • Net income was approximately $300,000 in 2022 compared to a net loss of about $900,000 in 2021.
  • Sales of radiochemical products accounted for approximately 54% of our total sales in 2022 as compared to 44% in 2021.
  • Cost of revenues for 2022 increased approximately 25% compared to 2021 and gross profit percentage decreased to 56% for 2022, from 59% in 2021.

INTERNATIONAL ISOTOPES INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER AND FIRST NINE-MONTHS 2022

Retrieved on: 
Wednesday, November 16, 2022
First, Growth, Medicine, COVID, Isotope, General Administration of Press and Publication, OTCQB, G&A, Cobalt, INIS, Income, I-131, IDAHO, Sale, Company, Research, Nuclear medicine, Administration, COVID-19, Sodium iodide, CEO, Animal, Bookkeeping, Air cargo

IDAHO FALLS, Idaho, Nov. 16, 2022 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company" or "INIS") announces its financial results for the three and nine months ended September 30, 2022.

Key Points: 
  • IDAHO FALLS, Idaho, Nov. 16, 2022 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company" or "INIS") announces its financial results for the three and nine months ended September 30, 2022.
  • Revenue for the nine-month period ended September 30, 2022, was $8,031,522, as compared to $7,369,922 for the same period in 2021, an increase of approximately 9%.
  • Cost of sales for the three month and nine-month periods ended September 30, 2022, increased approximately 30% and 15% respectively compared to the same periods in 2021.
  • Operating expense increased approximately 22% and 19% for the three- and nine-month periods respectively ended September 30, 2022.

‘Cannabis Dispensary of the Future’ NOXX Announces New Cookies Dispensary Partnership in Grand Rapids

Retrieved on: 
Tuesday, October 18, 2022
Natural Resources, Alternative Medicine, Other Retail, Health, Tobacco, Specialty, Cannabis, Retail, Cannabis, 28th Street, Ann Street, I-131, Billboard, Multimedia, Ad Age, Collection, Partnership, History, CEO, Genetics, Smoker, Leadership, Drug, Grocery store

The partnership marks the latest phase of NOXXs community-focused growth plan, where NOXXs flagship Grand Rapids dispensary on 28th Street has already served thousands in the West Michigan community.

Key Points: 
  • The partnership marks the latest phase of NOXXs community-focused growth plan, where NOXXs flagship Grand Rapids dispensary on 28th Street has already served thousands in the West Michigan community.
  • Cookies is one of the most well-respected cannabis brands in the world and NOXX is proud to bring the largest selection of Cookies proprietary genetics and world-class products to Grand Rapids, said Tommy Nafso, CEO and founder of NOXX.
  • NOXX is brewing something special in Michigan and this partnership with Cookies drastically increases access to top-shelf cannabis in Grand Rapids thriving cannabis community.
  • To learn more about Cookies, visit cookies.co , and to learn more about Cookies CBD, visit https://shop.cookies.co/
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221018005426/en/

Children’s Hospital Los Angeles Offers MIBG Therapy for Neuroblastoma

Retrieved on: 
Thursday, July 14, 2022
Oncology, Nursing, Education, Health, Hospitals, Radiology, Training, Blog, U.S. News & World Report, Radiation, Hematology, Multimedia, Child, Keck School of Medicine of USC, I-131, YouTube, LinkedIn, Travel, Food and Drug Administration, Patient, Medicine, MD, Instagram, Â, Radioactive decay, Food, Organ transplantation, Parent, Physician, Facility, USC, Brain, National Institutes of Health, Children's Hospital Los Angeles, New Approach, Hospital, Pediatrics, MS, Randomized controlled trial, News, Iodine, Twitter, Southwestern United States, Immunotherapy, Children and Family Court Advisory and Support Service, National, Medical imaging, Pharmaceutical industry, MIBG, Cancer, Facebook, Neuroblastoma

View the full release here: https://www.businesswire.com/news/home/20220714005155/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220714005155/en/
    Childrens Hospital Los Angeles offers MIBG Therapy for Neuroblastoma (Photo: Business Wire)
    MIBG (metaiodobenzylguanidine) is a compound that was once a blood pressure medicine and is easily absorbed by neuroblastoma cells.
  • Bringing MIBG therapy to Childrens Hospital Los Angeles will allow many more patients to access this promising treatment, says Araz Marachelian, MD, MS , Director of the Neuroblastoma Program in the Cancer and Blood Disease Institute at Childrens Hospital Los Angeles.
  • That phase 1 trial is led by the New Approaches to Neuroblastoma Therapy (NANT) consortium, which is headquartered at Childrens Hospital Los Angeles.
  • Founded in 1901, Childrens Hospital Los Angeles is the largest provider of care for children in Los Angeles County.

Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa

Retrieved on: 
Tuesday, April 12, 2022
ACT, Medication, AWE, Orphan, Acute myeloid leukemia, AML, CD45, NYSE, SEC, European Medicines Agency, CEO, Salvage therapy, Scientific Advice Mechanism, Antibody, Lymphatic system, Science, Security (finance), Leukemia, Population, I-131, CHMP, Committee for Medicinal Products for Human Use, ARCS, IDH, CD19, U.S. Securities and Exchange Commission, EMA, Toxic epidermal necrolysis, Refractory, Radiation, Degenerative disease, Patent, Annual report, ARC, Fred Hutchinson Cancer Research Center, SLG, FDA, Haematopoietic system, Patient, Form 10-Q, Company, Pharmacovigilance, Marketing, Adoptive cell transfer, Venetoclax, European Directive on Traditional Herbal Medicinal Products, Bone marrow, FLT3, Committee, Relapse, Pharmaceutical industry, Actinium, BMT, EU

NEW YORK and STOCKHOLM , April 12, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs, and Immedica Pharma AB ("Immedica") today announced entering a license and supply agreement for Iomab-B, an Antibody Radiation Conjugate comprised of apamistamab, a CD45 targeting antibody, and the radioisotope iodine-131 that is being developed for targeted conditioning to facilitate bone marrow transplant (BMT) and other cell and gene therapies. A pivotal Phase 3 trial, Study of Iomab-B versus Conventional Care in Elderly, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA), of Iomab-B completed patient enrollment in the third quarter of 2021 with topline data expected in the third quarter of 2022. BMT is the only potentially curative treatment option for patients with active, relapsed or refractory acute myeloid leukemia (AML).

Key Points: 
  • Sandesh Seth, Actinium's Chairman and CEO, said, "Immedica has established a strong team and impressive capabilities to commercialize specialty products in Europe, the Middle East and North Africa.
  • We are excited to partner with Immedica to work to bring Iomab-B to patients with AML in Europe, the Middle East and North Africa who may benefit from a potentially curative transplant."
  • "We are excited about the opportunity to make Iomab-B accessible for patients in Europe, the Middle East and North Africa.
  • We also look forward to deepening our collaboration with Actinium to bring the best possible support to AML treatment centers and health care professionals in Europe, the Middle East and North Africa", says Anders Edvell, CEO at Immedica.

INTERNATIONAL ISOTOPES INC. ANNOUNCES 2021 YEAR END FINANCIAL RESULTS

Retrieved on: 
Monday, April 4, 2022
Company, Positron emission tomography, Nuclear medicine, I-131, Primary energy, IDAHO, Coronavirus, INIS, LLC, DOE, COVID-19, OTCQB, Income, Department, FDA, PET, Animal, Pharmaceutical industry, Cobalt

IDAHO FALLS, Idaho, April 4, 2022 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company") announces its financial results for the fiscal year ended December 31, 2021. 

Key Points: 
  • IDAHO FALLS, Idaho, April 4, 2022 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company") announces its financial results for the fiscal year ended December 31, 2021.
  • Total revenues in 2021 were approximately $9.6 million compared to approximately $9.3 million in 2020, which represents an increase of approximately 3%.
  • Purchased the remaining 75.5% of RadQual, LLC, making RadQual, LLC and TI Services, LLC wholly-owned subsidiaries of International Isotopes, Inc.
  • Sales of the Company's radiochemical products accounted for approximately 44% of our total sales revenue in 2021 and 2020.

INTERNATIONAL ISOTOPES INC. ANNOUNCES COMPLETION OF AN ASSET PURCHASE AGREEMENT WITH PHARMALOGIC HOLDINGS CORP.

Retrieved on: 
Tuesday, February 22, 2022
IDAHO, Securities Exchange Act of 1934, Security (finance), Annual report, Isotope, Company, Sale, Nuclear Regulatory Commission, Title 21 CFR Part 11, U.S. Securities and Exchange Commission, Acquisition, I-131, INIS, Thyroid cancer, Calibration, NRC, FDA, Molecular reference standards, Sodium iodide, OTCQB, Securities Act of 1933, Drug Quality and Security Act, CFR, CEO, Nuclear medicine

IDAHO FALLS, Idaho, Feb. 22, 2022 /PRNewswire/ --International Isotopes Inc. (OTCQB: INIS) ("International Isotopes" or "INIS") is pleased to announce it has completed an asset purchase agreement with Pharmalogic Holdings Corp. for assets contained within most of the square footage of INIS's new contract manufacturing facility.

Key Points: 
  • IDAHO FALLS, Idaho, Feb. 22, 2022 /PRNewswire/ --International Isotopes Inc. (OTCQB: INIS) ("International Isotopes" or "INIS") is pleased to announce it has completed an asset purchase agreement with Pharmalogic Holdings Corp. for assets contained within most of the square footage of INIS's new contract manufacturing facility.
  • Pharmalogic Holdings Corp. is a portfolio company of Webster Equity Partners and MedEquity Capital, (the "investors").
  • The purchase price for the acquired assets was 4 million dollars, which was paid in full at closing.
  • INIS acquired the new contract manufacturing facility with all installed assets in December 2020 as a part of a settlement agreement with another company.